Portal de investigación
- Inicio
- Proyectos y Estudios
- ESTUDIO DE EXTENSIÓN MULTICÉNTRICO, DOBLE CIEGO Y ABIERTO PARA EVALUAR LA EFICACIA Y SEGURIDAD DE LIGELIZUMAB COMO RETRATAMIENTO, TERAPIA AUTOADMINISTRADA Y MONOTERAPIA EN PACIENTES CON URTICARIA CRÓNICA ESPONTÁNEA QUE HAN COMPLETADO LOS ESTUDIOS CQGE031C 2302, CQGE031C2303, CQGE031C2202 O CQGE031C1301.
ESTUDIO DE EXTENSIÓN MULTICÉNTRICO, DOBLE CIEGO Y ABIERTO PARA EVALUAR LA EFICACIA Y SEGURIDAD DE LIGELIZUMAB COMO RETRATAMIENTO, TERAPIA AUTOADMINISTRADA Y MONOTERAPIA EN PACIENTES CON URTICARIA CRÓNICA ESPONTÁNEA QUE HAN COMPLETADO LOS ESTUDIOS CQGE031C 2302, CQGE031C2303, CQGE031C2202 O CQGE031C1301.
Datos básicos
- Protocolo:
- CQGE031C2302E1
- EUDRACT:
- 2019-001792-37
- NCT:
- Centro:
- HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE
- Año de incio:
- 2020
- Año de finalización:
- 2025
Documentos
- No hay documentos
Participantes
Grupos
Financiadores - Promotores
Resultados del Ensayo Clínico
[[Translated article]]Drug Survival in Cyclosporine Treatment for Moderate to Severe Atopic Dermatitis: Analysis of the Spanish Atopic Dermatitis Registry (BIOBADATOP).
Couselo-Rodríguez C; (...); Flórez Á
Article. 10.1016/j.ad.2023.07.028. 2024
[[Translated article]]Epidemiological, Clinical, and Allergic Profile of Psoriatic Patients. Evaluation of the Spanish Registry of Contact Dermatitis and Cutaneous Allergy (REIDAC).
Verdaguer-Faja, J.; (...); Carrascosa, J. M.
Article. 10.1016/j.ad.2024.04.013. 2024
[[Translated article]]RF-Personalized Medicine to Treat Atopic Dermatitis: In Search for Predictive Biomarkers.
Lasheras-Perez, M A, Navarro-Blanco, F, Rodriguez-Serna, M
Article. 10.1016/j.ad.2024.04.007. 2024
[Translated article] BIOBADATOP Spanish Atopic Dermatitis Registry: Description and Early Findings.
Munera-Campos M; (...); Carrascosa JM
Article. 10.1016/j.ad.2023.05.010. 2023
[Translated article] Cybersecurity: a priority for pharmacy services in the age of artificial intelligence
Marin, Cayetano M. Hernandez, Monte-Boquet, Emilio, Andres, Jose Luis Poveda
Editorial Material. 10.1016/j.farma.2024.08.009. 2024
[Translated article] Epidemiological, Clinical, and Allergy Profile of Patients With Atopic Dermatitis and Hand Eczema: Evaluation of the Spanish Contact Dermatitis Registry (REIDAC).
Mora-Fernandez, V; (...); Carrascosa, J M
Article. 10.1016/j.ad.2022.02.015. 2022
[Translated article] Four-year Epidemiological Surveillance of the Spanish Registry of Research in Contact Dermatitis and Cutaneous Allergy: Current Situation and Trends.
Tous-Romero F; (...); Ortiz-de Frutos J
Article. 10.1016/j.ad.2024.02.006. 2024
[Translated article] Good humanisation practices in the healthcare of patients with rare diseases in Pharmacy Services
Company Albir MJ, Andrés JLP, Solsona MDE
Article. 10.1016/j.farma.2023.10.004. 2024
[Translated article] Moderate to Severe Psoriasis in Pediatric and Young Patients: The BIOBADADERM Registry Experience.
Nieto Benito, L M; (...); Garcia-Doval, I
Article. 10.1016/j.ad.2021.05.027. 2022
[Translated article] New challenges in advanced therapies.
Megías-Vericat JE; (...); Poveda Andrés JL
Article. 10.1016/j.farma.2024.05.001. 2024
[Translated article] Pharmacokinetic-guided switching from standard half-life factor VIII to extended half-life pegylated factor VIII in haemophilia A therapy in clinical practice.
Chovi-Trull, Maria; (...); Andres, Jose Luis Poveda
Article. 10.1016/j.farma.2024.12.007. 2025
[Translated article] Real-world effectiveness and safety of nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma.
Fernandez, Laura Lorente; (...); Andres, Jose Luis Poveda
Article. 10.1016/j.farma.2024.09.006. 2024
[Translated article] RF-Longer Dupilumab Dosing Intervals in Atopic Dermatitis: Optimization or Therapeutic Failure?
Lasheras-Perez, M A, Navarro-Blanco, F, Rodriguez-Serna, M
Article. 10.1016/j.ad.2024.07.008. 2024
2019 SEFH National Survey: service portfolio, care activities, education and research in Spain's hospital pharmacy departments.
Pérez-Encinas M; (...); Calleja-Hernández MÁ
Article. 10.7399/fh.11611. 2021
2-Hydroxyethyl methacrylate (2-HEMA) sensitization, a global epidemic at its peak in Spain?
Gatica-Ortega ME; (...); Borrego L
Article. 10.1111/cod.14520. 2024
A multicriteria decision analysis (MCDA) applied to three long-term prophylactic treatments for hereditary angioedema in Spain
Zozaya, Neboa; (...); Hidalgo-Vega, Alvaro
Article. 10.33393/grhta.2022.2333. 2022
A multi-criteria decision analysis on the value of nintedanib for interstitial lung diseases.
Zozaya, Neboa; (...); Verde, Luis
Article. 10.1017/S0266462322000459. 2022
A Non-Interventional, Multicenter Study to Characterize the Socio-Demographics, Clinical Characteristics, and Management of Generalized Pustular Psoriasis Patients in Spain: IMPULSE Study
Puig, Lluis; (...); IMPULSE Investigators Grp
Article. 10.1159/000540019. 2024
Allergic contact dermatitis in adults with and without atopic dermatitis: Evaluation of the Spanish Contact Dermatitis Registry (REIDAC).
Chicharro P; (...); Sánchez-Pérez J
Article. 10.1111/cod.14672. 2024
Allergic contact dermatitis to alkyl glucosides: Epidemiological situation in Spain.
Tous-Romero, Fatima; (...); Ortiz-de Frutos, Francisco Javier
Letter. 10.1111/jdv.18595. 2022
Analysis of chemical contamination by hazardous drugs with BD HD Check(R) system in a tertiary hospital
Valero García S; (...); Poveda Andrés JL
Article. 10.1177/10781552211038518. 2021
Assessing the value of moderate-to-severe atopic dermatitis treatment using multi-criteria decision analysis (MCDA).
Pereyra-Rodríguez JJ; (...); Ortiz de Frutos FJ
Letter. 10.1111/jdv.19432. 2023
Atypical bullae in hands and trunk: An unusual suspect
Palacios-Diaz, Rodolfo David, Lasheras-Perez, Miguel Antonio, Rodriguez-Serna, Mercedes
Editorial Material. 10.1016/j.eimc.2023.12.010. 2024
Atypical bullae in hands and trunk: An unusual suspect.
Palacios-Diaz, Rodolfo David, Lasheras-Perez, Miguel Antonio, Rodriguez-Serna, Mercedes
Case Reports. 10.1016/j.eimce.2023.12.003. 2024
Baricitinib against severe COVID-19: effectiveness and safety in hospitalised pretreated patients.
Iglesias Gómez R; (...); Poveda Andrés JL
Article. 10.1136/ejhpharm-2021-002741. 2021
Bioavailability of once-daily tacrolimus formulations used in clinical practice in the management of De Novo kidney transplant recipients: the better study.
Fernandez Rivera C; (...); Hernandez D
Article. 10.1111/ctr.14550. 2022
BIOBADATOP Spanish Atopic Dermatitis Registry: Description and Early Findings.
Munera-Campos M; (...); Carrascosa JM
Article. 10.1016/j.ad.2023.03.001. 2023
Candidate Allergens for Inclusion in the Spanish Standard Series Based on Data from the Spanish Contact Dermatitis Registry.
Hernández-Fernández CP; (...); Borrego Hernando L
Article. 10.1016/j.ad.2021.05.005. 2021
Certolizumab pegol effectiveness, survival and safety in patients with psoriasis: A multicenter retrospective analysis in daily clinical practice by the Spanish Psoriasis Group
Sahuquillo-Torralba, Antonio; (...); Gallardo, Fernando
Article. 10.1111/ijd.17238. 2024
Clinical benefits of a Bayesian model for plasma-derived factor VIII/VWF after one year of pharmacokinetic-guided prophylaxis in severe/moderate hemophilia A patients
Megias-Vericat, JE; (...); Poveda, JL
Article. 10.1016/j.thromres.2021.07.009. 2021
Clinicopathological characteristics of cutaneous and mucocutaneous leishmaniasis in patients treated with TNF-alpha inhibitors.
Palacios-Diaz, Rodolfo David; (...); Botella-Estrada, Rafael
Article. 10.1111/ddg.15007. 2023
Consensus recommendations for the improvement of inter- and intra-centre care coordination in the management of hemophilia.
Montoro-Ronsano JB; (...); Soto-Ortega I
Article. 10.1016/j.farma.2023.01.003. 2023
Consensus recommendations for the improvement of inter- and intra-centre care coordination in the management of hemophilia.
Montoro-Ronsano, Jose Bruno; (...); Soto-Ortega, Inmaculada
Article. 10.1016/j.farma.2023.04.002. 2023
COST-EFFECTIVENESS ANALYSIS OF DIFELIKEFALIN FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE ASSOCIATED-PRURITUS IN SPAIN
Sanchez-Alvarez, Emilio E.; (...); Hernaez Colque, M.
Meeting Abstract. 2024
COSTS OF THE MANAGEMENT OF HEMOPHILIA A WITH INHIBITORS IN SPAIN
Bonanad, S; (...); Gonzalez-Dominguez, A
Meeting Abstract. 2020
Costs of the management of hemophilia A with inhibitors in Spain
Bonanad, S; (...); Gonzalez-Dominguez, A
Article. 10.33393/grhta.2021.2234. 2021
Cutaneous sarcoidosis after platelet-rich plasma injections and permanent eyebrow make-up.
Torregrosa DM; (...); Estrada RB
Case Reports. 10.1016/j.ad.2023.06.023. 2024
Cybersecurity, a priority for pharmacy services in the age of artificial intelligence.
Hernández Marín CM, Monte-Boquet E, Poveda Andrés JL
Editorial Material. 10.1016/j.farma.2024.08.001. 2024
Characterizing chronic hepatitis delta in Spain and the gaps in its management
Rodriguez-Tajes, Sergio; (...); Lens, Sabela
Meeting Abstract. 2023
Characterizing Hepatitis Delta in Spain and the gaps in its management.
Rodriguez-Tajes, Sergio; (...); Lens, Sabela
Article. 10.1016/j.gastrohep.2024.502222. 2024
Design and rationale for a real-world prospective, multicenter registry of myocardial revascularization failure and secondary revascularization: The REVASEC study.
Salinas P; (...); Escaned J
Article. 10.1016/j.carrev.2021.11.015. 2021
Determining value in the treatment of activated PI3Kdelta syndrome in Spain: a multicriteria decision analysis from the perspective of key stakeholders.
Abad, Maria Reyes; (...); Gil, Alicia
Article. 10.33393/grhta.2024.3041. 2024
Determining what represents value in the treatment of prurigo nodularis and its key unmet needs in Spain through Multi-Criteria Decision Analysis
Silvestre, Juan Francisco; (...); Serra-Baldrich, Esther
Article. 10.1002/jvc2.275. 2024
Differences in epidemiology, comorbidities and treatment choice between plaque psoriasis and pustular psoriasis: results from the Biobadaderm registry.
Ruiz Genao, Diana P.; (...); Garcia-Doval, Ignacio
Letter. 10.1111/bjd.21763. 2022
DNA Copy Number Variation Associated with Anti-tumour Necrosis Factor Drug Response and Paradoxical Psoriasiform Reactions in Patients with Moderate-to-severe Psoriasis
Sanz-Garcia, A; (...); Ovejero-Benito, MC
Article. 10.2340/00015555-3794. 2021
Dose reduction is a feasible strategy in patients with plaque psoriasis who achieve sustained response with secukinumab: a retrospective, multicenter cohort study in daily practice setting
Daudén E; (...); Llamas-Velasco M
Article. 10.1111/ijd.16915. 2024
Dose tapering of dupilumab in patients with persistently controlled atopic dermatitis: a Spanish multicenter cohort study
Lasheras-Pérez MA; (...); Rodríguez-Serna M
Article. 10.1111/ijd.17030. 2024
Drug survival and safety of biosimilars and originator adalimumab in the treatment of psoriasis: a multinational cohort study.
Phan, Duc Binh; (...); Yiu ZZN
Article. 10.1136/bmjopen-2023-075197. 2023
Drug Survival and Safety of Biosimilars Compared with Originator Adalimumab for Psoriasis: A Multinational Cohort Study
Duc Binh Phan; (...); Yiu, Zenas Zee Ngai
Meeting Abstract. 2024
Drug Survival and Safety of Biosimilars Compared with Originator Adalimumab for Psoriasis: A Multinational Cohort Study.
Phan, Duc Binh; (...); Yiu, Zenas Z N
Article. 10.1093/bjd/ljae454. 2024
Drug survival of adalimumab biosimilars in real-world treatment of psoriasis: A Spanish multicenter study
Lopez-Ferrer, Anna; (...); Puig, Lluis
Article. 10.1111/dth.15831. 2022
Dupilumab for atopic dermatitis during pregnancy and breastfeeding: Clinical experience in 13 patients.
Escolà H; (...); Curto-Barredo L
Letter. 10.1111/jdv.19165. 2023
Efecto de la adición de fortificantes y de módulo de proteínas en la osmolalidad de la leche materna donada.
Torres Martínez E; (...); Vento M
Article. 10.1016/j.anpedi.2020.03.009. 2020
Effect of Sex in Systemic Psoriasis Therapy: Differences in Prescription, Effectiveness and Safety in the BIOBADADERM Prospective Cohort
Hernandez-Fernandez, CP; (...); Garcia-Doval, I
Article. 10.2340/00015555-3711. 2021
Effectiveness and safety of brodalumab in the treatment of plaque, scalp and palmoplantar psoriasis: A multicentre retrospective study in a Spanish population.
Sahuquillo-Torralba, A; (...); Botella-Estrada, R
Article. 10.1111/ajd.14130. 2023
Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group.
del Alcazar, Elena; (...); Carrascosa YJM
Article. 10.1111/dth.15231. 2022
Effectiveness of Caplacizumab Nanobody in Acquired Thrombotic Thrombocytopenic Purpura Refractory to Conventional Treatment
Palanques-Pastor T; (...); Poveda Andrés JL
Article. 10.1159/000517813. 2021
Effectiveness of Secukinumab for the treatment of erythrodermic psoriasis. Multicenter study in daily practice.
Reymundo, A; (...); Dauden, E
Letter. 10.1111/jdv.19371. 2023
Efficacy of Risankizumab in Patients with Suboptimal Response or Failure to Ustekinumab: A Multicenter Retrospective Study in Spain
Magdaleno-Tapial, Jorge; (...); Martorell-Calatayud, Antonio
Article. 10.1155/2024/5528484. 2024
Emicizumab-induced photosensitivity.
Asensi Canto, Pedro; (...); Haya Guaita, Saturnino
Article. 10.1055/s-0042-1749092. 2022
Epidemiological, Clinical, and Allergic Profile of Psoriatic Patients. Evaluation of the Spanish Registry of Contact Dermatitis and Cutaneous Allergy (REIDAC).
Verdaguer-Faja J; (...); Carrascosa JM
Article. 10.1016/j.ad.2024.02.009. 2024
Epidemiological, Clinical, and Allergy Profile of Patients With Atopic Dermatitis and Hand Eczema: Evaluation of the Spanish Contact Dermatitis Registry (REIDAC).
Mora-Fernandez, V; (...); Carrascosa, J. M.
Article. 10.1016/j.ad.2021.10.002. 2022
Fast and sustained improvement of patient-reported outcomes in psoriatic patients treated with secukinumab in a daily practice setting
Chicharro, Pablo; (...); Dauden, Esteban
Article. 10.1111/dth.15653. 2022
Fetal exposure to tofacitinib during the first trimester: A healthy newborn case report
Fernandez-Sanchez, M; (...); Poveda-Andres, JL
Article. 10.1002/bdr2.1942. 2021
Four-year epidemiological surveillance of the Spanish Registry of Contact Dermatitis and Cutaneous Allergy (REIDAC): Current situation and trends.
Romero FT; (...); de Frutos JO
Article. 10.1016/j.ad.2023.10.039. 2024
Genetic polymorphisms to identify patients with an optimal response to tildrakizumab in psoriasis patients from real-life clinical practice.
Butrón-Bris B; (...); de la Fuente H
Article. 10.1111/exd.15152. 2024
Genetic Variants Associated with Biological Treatment Response in Inflammatory Bowel Disease: A Systematic Review.
Plaza J; (...); Moret-Tatay I
Article. 10.3390/ijms25073717. 2024
Guide to Good Humanization Practices in Patients with Rare Diseases. who vadis
Editorial Material. 2022
Guselkumab, Risankizumab, and Tildrakizumab demonstrate parallel effectiveness and safety in psoriasis treatment: a head-to-head comparative study in real clinical practice.
Mansilla-Polo M; (...); Botella-Estrada R
Article. 10.1016/j.abd.2024.04.004. 2024
Healthcare Resource Utilization among Patients between 60-75 Years with Secondary Acute Myeloid Leukemia Receiving Intensive Chemotherapy Induction: A Spanish Retrospective Observational Study
Solana-Altabella, Antonio; (...); Martinez-Cuadron, David
Article. 10.3390/cancers14081921. 2022
High adherence to secukinumab in patients with moderate to severe psoriasis: a long-term multicenter study in a daily practice setting
Martos-Cabrera, Luisa; (...); Dauden, Esteban
Letter. 10.1111/ijd.16365. 2022
High incidence of pulmonary thromboembolism in hospitalized SARS-CoV-2 infected patients despite thrombo-prophylaxis.
El-Qutob D; (...); Carrera-Hueso FJ
Article. 10.1016/j.hrtlng.2022.02.003. 2022
Hospital pharmacy initiatives for improving the management of patients with congenital coagulopathies
Bruno Montoro-Ronsano, Jose; (...); Alberto Vella, Vincenzo
Article. 10.7399/fh.11729. 2022
Hospitalization budget impact during the COVID-19 pandemic in Spain.
Carrera-Hueso, F. J.; (...); Crespo-Palomo, C.
Article. 10.1186/s13561-021-00340-0. 2021
How can artificial intelligence optimize value-based contracting?
Poveda, Jose Luis; (...); Medrano, Ignacio H.
Letter. 10.1186/s40545-022-00475-3. 2022
IMAPSORS project: A multicenter validation study to assess the accuracy of an artificial intelligence solution to quantify psoriasis severity
Martorell, A; (...); Llamas, M
Meeting Abstract. 2021
Impact of combinations of single-nucleotide polymorphisms of anthracycline transporter genes upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia.
Megías-Vericat JE; (...); Montesinos P
Article. 10.1080/10428194.2020.1839650. 2020
Incidence of severe COVID-19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: a Biobadaderm cohort analysis.
Baniandrés-Rodríguez O; (...); García-Doval I
Letter. 10.1016/j.jaad.2020.10.046. 2021
Influence of polymorphisms in anthracyclines metabolism genes in the standard induction chemotherapy of acute myeloid leukemia.
Megías-Vericat JE; (...); Montesinos P
Article. 10.1097/FPC.0000000000000431. 2021
Innovations of Spanish code of medical deontology
Lasheras-Pérez MA; (...); Unamuno Bustos B
Letter. 10.1016/j.semerg.2023.102137. 2024
Is erenumab an efficient alternative for the prevention of episodic and chronic migraine in Spain? Results of a cost-effectiveness analysis.
Pozo-Rosich P; (...); Irimia P
Article. 10.1186/s10194-024-01747-w. 2024
Isavuconazole Pharmacokinetics in Critically Ill Patients: Relationship with Clinical Effectiveness and Patient Safety.
Martin-Cerezuela, Maria; (...); Ramirez Galleymore, Paula
Article. 10.3390/antibiotics13080706. 2024
Klinisch-pathologische Eigenschaften kutaner und mukokutaner Leishmaniose bei mit TNF-a-Inhibitoren behandelten Patienten.
Palacios-Diaz, Rodolfo David; (...); Botella-Estrada, Rafael
Article. 10.1111/ddg.15007_g. 2023
La eutanasia en el régimen penitenciario español.
Lasheras-Pérez MA; (...); Rodríguez-Serna M
Letter. 10.1016/j.semerg.2024.102219. 2024
Leishmaniasis in patients undergoing biologic and immunosuppressive treatment: Case-control multicenter study
Sahuquillo-Torralba, A; (...); Rocamora, V
Meeting Abstract. 2020
Longer dupilumab dosing intervals in atopic dermatitis: optimization or therapeutic failure?
Lasheras-Pérez MA, Navarro-Blanco F, Rodríguez-Serna M
Article. 10.1016/j.ad.2023.04.043. 2024
Long-term follow-up of HCV-infected patients with end-stage chronic kidney disease after sustained virological response with direct-acting antiviral therapy
Martinez-Camprecios, Joan; (...); Buti, Maria
Article. 10.1016/j.gastrohep.2022.12.004. 2023
Management of flexible cavovarus foot in patients with Charcot-Marie-Tooth disease: midterm results.
Megías-Vericat JE; (...); Poveda-Andrés JL
Article. 2021
Manipulación de fármacos para su administración por gastrostomía endoscópica percutánea en pacientes con esclerosis lateral amiotrófica y nutrición enteral.
Vázquez Polo A; (...); Vázquez Costa JF
Article. 10.20960/nh.03946. 2022
Matching-Adjusted Indirect Comparison of Efficacy and Consumption of rVIII-SingleChain Versus Two Recombinant FVIII Products Used for Prophylactic Treatment of Adults/Adolescents with Severe Haemophilia A
Bonanad, S; (...); Santos, S
Article. 10.1007/s12325-021-01853-0. 2021
Metabolic Phenotyping in Prostate Cancer Using Multi-Omics Approaches.
Gomez-Cebrian, Nuria; (...); Puchades-Carrasco, Leonor
Article. 10.3390/cancers14030596. 2022
MiR-138-5p Suppresses Cell Growth and Migration in Melanoma by Targeting Telomerase Reverse Transcriptase.
Tarazon, Estefania; (...); Botella Estrada, Rafael
Article. 10.3390/genes12121931. 2021
Moderate to Severe Psoriasis in Pediatric and Young Patients: The BIOBADADERM Registry Experience.
Nieto Benito LM; (...); García-Doval I
Case Reports. 10.1016/j.ad.2021.05.017. 2022
Monitoring coagulation factors during surgery. A systematic review
Eduardo Megias-Vericat, Juan; (...); Luis Poveda-Andres, Jose
Review. 10.7399/fh.11766. 2021
Monitoring contamination of hazardous drug compounding surfaces at hospital pharmacy departments. A consensus Statement. Practice guidelines of the Spanish Society of Hospital Pharmacists (SEFH).
Valero-García S; (...); Delgado-Sánchez O
Article. 10.7399/fh.11655. 2021
Multi-Omic Approaches to Breast Cancer Metabolic Phenotyping: Applications in Diagnosis, Prognosis, and the Development of Novel Treatments
Gomez-Cebrian, N; (...); Pineda-Lucena, A
Review. 10.3390/cancers13184544. 2021
National Survey of the SEFH-2019: portfolio of services, healthcare activity, teaching and research in Hospital Pharmacy Services in Spain (vol 45, pg 32, 2021)
Perez-Encinas, Montserrat; (...); Angel Calleja-Hernandez, Miguel
Correction. 10.7399/fh.11740. 2021
National Survey on the Use of Mobile Applications in Patients with Hemophilia and Other Coagulopathies
Eduardo Megias, Juan; (...); Poveda Andres, Jose Luis
Meeting Abstract. 10.1182/blood-2022-169938. 2022
New challenges of advanced therapies.
Megías-Vericat JE; (...); Poveda Andrés JL
Article. 10.1016/j.farma.2023.11.008. 2024
Observational study to evaluate discontinuation of monotherapy with cobicistat-boosted darunavir in patients with human immunodeficiency virus
Solana-Altabella, Antonio; (...); Poveda-Andres, Jose Luis
Article. 10.1097/MD.0000000000032208. 2022
ODs with a positive TPR conclusion, not subject to a conditional approval, and approved without requering a pass would be more likely to be reimbursed in Spain.
Poveda JL; (...); Badia X
Article. 10.1186/s13023-022-02610-4. 2023
Omics-Based Approaches for the Characterization of Pompe Disease Metabolic Phenotypes
Gomez-Cebrian, Nuria; (...); Puchades-Carrasco, Leonor
Review. 10.3390/biology12091159. 2023
One Dose Risankizumab Effectiveness in Psoriasis: A Real-Life Multicentre Study
Magdaleno-Tapial, Jorge; (...); Sanchez-Carazo, Jose Luis
Article. 10.1155/2024/4866592. 2024
OPTIMIZING MANAGEMENT AND OUTCOMES OF ACTIVATED PHOSPHOINOSITIDE 3-KINASE DELTA SYNDROME (APDS) IN SPAIN: BEWAYAPDS PROJECT
Flores-Moreno, S.; (...); Gil, A.
Meeting Abstract. 2024
Paracetamol vs. Ibuprofen in Preterm Infants With Hemodynamically Significant Patent Ductus Arteriosus: A Non-inferiority Randomized Clinical Trial Protocol (vol 8, 372, 2020)
Garcia-Robles, Ana; (...); Aguar Carrascosa, Marta
Correction. 10.3389/fped.2021.834454. 2022
Patch test results to the Spanish baseline patch test series according to age groups: A multicentric prospective study from 2019 to 2023.
Pesqué D; (...); Giménez-Arnau AM
Article. 10.1111/cod.14702. 2024
Patch Testing in Patients With Severe Atopic Dermatitis Treated With Dupilumab: A Multicentric Approach in Spain.
Docampo-Simon, Alexandre; (...); Silvestre, Juan F.
Article. 10.1089/derm.2022.0023. 2023
Patient and health practitioner perceptions about the role of hospital pharmacists along the care continuum: the Fharmaconectados Project
Morillo-Verdugo, R; (...); Diaz-Olmo, J
Article. 10.7399/fh.11719. 2021
Patient and health practitioner perceptions about the role of hospital pharmacists along the care continuum: the Fharmaconectados Project.
Morillo-Verdugo R; (...); Díaz-Olmo J
Article. 2021
Personalized medicine to treat atopic dermatitis: in search for predictive biomarkers.
Lasheras-Perez, M A, Navarro-Blanco, F, Rodriguez-Serna, M
Article. 10.1016/j.ad.2023.02.041. 2024
Pharmacogenetic biomarkers for secukinumab response in psoriasis patients in real-life clinical practice.
Munoz-Aceituno, E.; (...); de la Fuente, H.
Article. 10.1111/jdv.19782. 2023
Pharmacogenetics in Response to Biological Agents in Inflammatory Bowel Disease: A Systematic Review.
Ballesta-Lopez, Octavio; (...); Poveda-Andres, Jose Luis
Article. 10.3390/ijms26041760. 2025
Pharmacometabolomics by NMR in Oncology: A Systematic Review.
Gómez-Cebrián N; (...); Pineda-Lucena A
Article. 10.3390/ph14101015. 2021
Pharmacotherapeutic management of advanced therapy medicinal products
Luis Poveda-Andres, Jose; (...); Valero-Garcia, Silvia
Article. 10.7399/fh.13036. 2022
Polysensitization in the Spanish Contact Dermatitis Registry (REIDAC): A 2019-2022 prospective study with cluster and network analysis.
Pesque, David; (...); Gimenez-Arnau, Ana Maria
Article. 10.1111/jdv.19934. 2024
Porto sinusoidal vascular liver disorder: natural history and long-term outcome
Magaz, Marta; (...); Garcia Pagan, Juan Carlos
Meeting Abstract. 2023
Porto-sinusoidal vascular liver disorder with portal hypertension: Natural History and Long-Term Outcome.
Magaz, Marta; (...); Garcia-Pagan, Juan Carlos
Article. 10.1016/j.jhep.2024.07.035. 2024
Preparation and administration of insulin infusions in neonatology: A national survey.
Garcia-Robles, Ana; (...); Aguar Carrascosa, Marta
Article. 10.1016/j.anpede.2020.06.015. 2021
Presence of good humanization practices in the healthcare of patients with rare diseases in Pharmacy Services
Company Albir MJ, Poveda Andrés JL, Edo Solsona MD
Article. 10.1016/j.farma.2023.06.0131130. 2024
Proactive therapeutic drug monitoring and pharmacogenetic analysis in inflammatory bowel disease: A systematic review
Ballesta-Lopez, Octavio; (...); Luis Poveda-Andres, Jose
Review. 10.7399/fh.11780. 2021
Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir.
Ruiz-Cobo, Juan Carlos; (...); Buti, Maria
Article. 10.1111/apt.18020. 2024
Real-life effectiveness of voxilaprevir/sofosbuvir/velpatasvir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir
Ruiz-Cobo, Juan Carlos; (...); Lens, Sabela
Meeting Abstract. 2023
Real-world Safety and Efficacy of Risankizumab in Psoriatic Patients: A Multicenter, Retrospective, and Not-interventional Study.
Martorell A; (...); Magdaleno-Tapial J
Article. 10.1016/j.ad.2024.10.042. 2024
Recommendations for the integral diagnosis of chronic viral hepatitis in a single analytical extraction.
Crespo, Javier; (...); Calleja, Jose Luis
Practice Guideline. 10.1016/j.gastrohep.2022.09.009. 2023
Recurrent alcohol-associated hepatitis is common and is associated with increased mortality.
Gratacos-Gines, Jordi; (...); Pose, Elisa
Article. 10.1097/HEP.0000000000000825. 2024
Rivaroxaban improves survival and decompensation in cirrhotic patients with moderate liver dysfunction. Double-blind, placebocontrolled trial
Puente Sanchez, Angela; (...); Garcia Pagan, Juan Carlos
Meeting Abstract. 2023
Safety of biologic therapy in combination with methotrexate in moderate to severe psoriasis: a cohort study from the BIOBADADERM registry.
Lluch-Galcera, Juan Jose; (...); Garcia-Doval, Ignacio
Article. 10.1093/bjd/ljad382. 2023
Safety of biosimilars compared with originator adalimumab for psoriasis: a multinational cohort study
Phan, Duc Binh; (...); Yiu, Zenas
Meeting Abstract. 10.1093/bjd/ljae360.068. 2024
Sarcoidosis cutánea tras inyecciones de plasma rico en plaquetas y maquillaje permanente de cejas.
Martín-Torregrosa D; (...); Botella-Estrada R
Article. 10.1016/j.ad.2024.10.043. 2024
Secukinumab is effective and safe in the treatment of recalcitrant palmoplantar psoriasis and palmoplantar pustular psoriasis in a daily practice setting.
Reolid, Alejandra; (...); Dauden, Esteban
Article. 10.1016/j.jaad.2022.05.047. 2022
SEFH National Survey-2019: general characteristics, staffing, material resources and information systems in Spain's hospital pharmacy departments.
Pérez-Encinas M; (...); Calleja-Hernández MÁ
Article. 10.7399/fh.11565. 2020
Sensitisation to textile dyes in Spain: Epidemiological situation (2019-2022).
Hernández Fernández CP; (...); Doval IG
Article. 10.1111/cod.14513. 2024
Sensitization to isothiazolinones in the Spanish Contact Dermatitis Registry (REIDAC): 2019-2021 epidemiological situation.
Hernandez Fernandez, Carlos Pelayo; (...); Garcia Doval, Ignacio
Article. 10.1111/cod.14251. 2022
Should methyldibromo glutaronitrile continue to be used in the European baseline Series? A REIDAC 1 national cross-sectional study.
Mercader-García P; (...); Borrego L
Article. 10.1111/cod.13837. 2021
SMPTall man lettering application in medication information systems as a quality and safety strategy in hospital organization
Iglesias Gomez, Ruben; (...); Poveda Andres, Jose Luis
Article. 10.1111/jcpt.13703. 2022
Sodium metabisulfite a current low relevant allergen in Spain.
Sanz-Sanchez, Tatiana; (...); Borrego, Leopoldo
Letter. 10.1111/jdv.19702. 2023
Standard and Expanded Series Patch Testing Update by the Spanish Contact Dermatitis and Skin Allergy Research Group (GEIDAC)
Navarro-Trivino, F. J.; (...); Armario-Hita, J. C.
Article. 10.1016/j.ad.2024.05.018. 2024
Standard and Expanded Series Patch Testing Update by the Spanish Contact Dermatitis and Skin Allergy Research Group (GEIDAC).
Navarro-Triviño FJ; (...); Carlos Armario-Hita J
Article. 10.1016/j.ad.2024.03.024. 2024
Survey to evaluate the implementation of the recommendations on the comprehensive diagnosis of viral hepatitis in a single extraction: where are we?
Cabezas, Joaquin; (...); Crespo, Javier
Meeting Abstract. 2023
SURVEY TO EVALUATE THE IMPLEMENTATION OF THE RECOMMENDATIONS ON THE COMPREHENSIVE DIAGNOSIS OF VIRAL HEPATITIS IN A SINGLE EXTRACTION: WHERE ARE WE?
Cabezas, Joaquin; (...); Crespo Garcia, Javier
Meeting Abstract. 2023
Sustained response to anti-TNF therapy in ASIA syndrome triggered by vaccination and filler.
Martin-Torregrosa, Daniel; (...); Rodriguez-Serna, Mercedes
Letter. 10.1111/ijd.17650. 2025
Switching from dupilumab to tralokinumab in patients with atopic dermatitis due to inefficacy or side effects.
Lasheras-Pérez MA; (...); Rodriguez-Serna M
Article. 10.1111/ijd.16926. 2024
Systematic Review of Pharmacogenetics of ABC and SLC Transporter Genes in Acute Myeloid Leukemia
Megías-Vericat JE; (...); Montesinos P
Review. 10.3390/pharmaceutics14040878. 2022
Systemic therapies for toxic epidermal necrolysis and Stevens-Johnson syndrome: A SCORTEN-based systematic review and meta-analysis
Torres Navarro, Ignacio; (...); Botella-Estrada, Rafael
Meeting Abstract. 2020
The association of salivary caffeine levels with serum concentrations in premature infants with apnea of prematurity
Garcia-Robles, Ana; (...); Saenz Gonzalez, Pilar
Article. 10.1007/s00431-022-04628-z. 2022
The contribution of fenfluramine to the treatment of Dravet syndrome in Spain through Multi-Criteria Decision Analysis.
Gil-Nagel A; (...); Gil A
Article. 10.1016/j.yebeh.2022.108711. 2022
The risk of hepatic adverse events of systemic medications for psoriasis: a prospective cohort study using the BIOBADADERM registry.
Munera-Campos, M; (...); Garcia-Doval, I
Article. 10.1080/09546634.2021.1922572. 2021
The value of the reflective discussion in decision-making using multi-criteria decision analysis (MCDA): an example of determining the value contribution of tabelecleucel for the treatment of the Epstein Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD).
Badia, Xavier; (...); Valles, Joan-Antoni
Article. 10.1186/s13023-024-03324-5. 2024
Towards a symbiotic relationship between big data, artificial intelligence, and hospital pharmacy
Del Rio-Bermudez, C; (...); Poveda, JL
Editorial Material. 10.1186/s40545-020-00276-6. 2020
Toxic-metabolic encephalopathy induced by metronidazole and disulfiram: classics never die.
Chovi-Trull, Maria; (...); Poveda-Andres, Jose Luis
Article. 10.1136/ejhpharm-2024-004184. 2024
Treatment of atopic dermatitis with abrocitinib in real practice in Spain: efficacy and safety results from a 24-week multicenter study
Armario-Hita, Jose Carlos; (...); Ruiz-Villaverde, Ricardo
Article. 10.1111/ijd.17344. 2024
VALUE CRITERIA FOR OUTCOMES BASED MANAGED ENTRY AGREEMENT OF CAR-T IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) THROUGH MCDA
Poveda, J. L.; (...); Lizan, L.
Meeting Abstract. 2023
Zoon's vulvitis in association with severe vulvodynia.
Abril-Perez, Carlos; (...); Botella-Estrada R
Article. 10.1016/j.ajog.2022.01.033. 2022